Report Scope:
This report aims to study the myasthenia gravis treatment global market size comprehensively. Current and historical market revenues can be estimated based on the product type, treatment by drug and region.

Report Includes:

  • 54 data tables and 47 additional tables
  • An overview and analysis of the global market for myasthenia gravis (MG) treatments
  • Analyses of market trends, with historical market revenue data (sales figures) for 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
  • Estimates of the market size, revenue forecasts and potential growth share analysis for MG treatments based on product, type, treatment modality, and region
  • In-depth information (facts and figures) pertaining to the major factors influencing the market (drivers, restraints, opportunities and challenges)
  • Analysis of the market growth opportunities through Porter’s Five Forces and PESTLE analyses, taking into consideration the prevailing micro- and macro environmental factors
  • An examination of the importance of ESG in the myasthenia gravis market, taking into account consumer attitudes, risks and opportunities, and the ESG practices of pharmaceutical and biotech companies
  • Discussion of the factors driving the market, industry trends and new developments
  • Analysis of relevant patents
  • Identification of the leaders in the field of MG
  • Profiles of the leading market players, including Profiles of the leading market players, including AbbVie, Bausch Health, Gilead Sciences, Merck & Co. Inc., Servier, and Teva